We graded 24 of the most searched peptide compounds by the quality of their published evidence and their regulatory status. The headline: most of what people research is far earlier-stage than the marketing suggests.
Each compound was placed in the strongest evidence tier its published research supports, from human randomized controlled trials down to in-vitro and preclinical work. Here is the distribution across all 24 compounds.
Only 8 of the 24 compounds have human randomized controlled trial evidence, and 5 have no completed human studies at all. 6 are approved by the FDA, and in every one of those cases the approval belongs to a specific branded drug for a specific condition, not to the research-chemical versions sold online.
The practical takeaway is to weight any claim by where its compound sits on this ladder. A result in mice is a starting point for research, not evidence of a benefit in people. This study describes the state of the evidence. It does not tell anyone to take, avoid, or obtain anything.
Free to reference with a link back to The Pep Expert. Copy the citation:
The Pep Expert (2026). State of Peptide Research 2026. https://thepepexpert.com/research/state-of-peptide-research-2026/
Medical disclaimer: This data study is educational reference only and is not medical advice, diagnosis, or treatment. Most peptides analyzed are research compounds not approved by the FDA for human use. Figures reflect The Pep Expert's evidence-tier assessment of published research as of July 2026. Consult a licensed healthcare provider before making any health decision. Methodology and per-compound detail are in the Peptide Evidence Explorer.